Revosimeline

Revosimeline is a muscarinic acetylcholine receptor agonist which has not been marketed at this time.^[1]^[2]^[3] It is said to be an agonist of the muscarinic acetylcholine M₁ receptor.^[3] The drug appears to be structurally distinct from earlier muscarinic acetylcholine receptor agonists like milameline and xanomeline.^[4] Its INN was designated in 2018.^[5]

References

↑ "Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024". World Health Organization. 2024. p. 102. https://iris.who.int/bitstream/handle/10665/379226/9789240099388-eng.pdf#page=145. "-meline cholinergic agents (muscarine receptor agonists/partial antagonists used in the treatment of Alzheimer’s disease) E.1.0.0 (USAN: cholinergic agonists (arecoline derivatives used in the treatment of Alzheimer's disease)) [...] alvameline (79), cevimeline (76), itameline (77), milameline (74), revosimeline (120), sabcomeline (76), tazomeline (77), xanomeline (70)"
↑ "Proposed INN: List 120: Revosimelinum". WHO Drug Information 32 (4): 674. 2018. https://www.prescrire.org/Docu/DOCSDCI/WHO_INN_ProposedList120.pdf#page=116. "p. 382 revosimelinum revosimeline [...] replace the mode of action by the following one [...] muscarinic receptor agonist [...]".
↑ ^3.0 ^3.1 "REVOSIMELINE". Inxight Drugs. National Center for Advancing Translational Sciences (NCATS). https://drugs.ncats.io/substance/9GHO88L89C.
↑ "Revosimeline". PubChem. U.S. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/133082878.
↑ "Recommended INN: List 80: revosimelinum". WHO Drug Information 32 (3): 482. 2018. https://iris.who.int/bitstream/handle/10665/330907/DI323-425-508-eng.pdf#page=58.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Revosimeline. Read more

[WHO2024-1] "Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024". World Health Organization. 2024. p. 102. https://iris.who.int/bitstream/handle/10665/379226/9789240099388-eng.pdf#page=145. "-meline cholinergic agents (muscarine receptor agonists/partial antagonists used in the treatment of Alzheimer’s disease) E.1.0.0 (USAN: cholinergic agonists (arecoline derivatives used in the treatment of Alzheimer's disease)) [...] alvameline (79), cevimeline (76), itameline (77), milameline (74), revosimeline (120), sabcomeline (76), tazomeline (77), xanomeline (70)"

[WHO2018a-2] "Proposed INN: List 120: Revosimelinum". WHO Drug Information 32 (4): 674. 2018. https://www.prescrire.org/Docu/DOCSDCI/WHO_INN_ProposedList120.pdf#page=116. "p. 382 revosimelinum revosimeline [...] replace the mode of action by the following one [...] muscarinic receptor agonist [...]".

[InxightDrugs-3] 3.0 ^3.1 "REVOSIMELINE". Inxight Drugs. National Center for Advancing Translational Sciences (NCATS). https://drugs.ncats.io/substance/9GHO88L89C.

[PubChem-4] "Revosimeline". PubChem. U.S. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/133082878.

[WHO2018b-5] "Recommended INN: List 80: revosimelinum". WHO Drug Information 32 (3): 482. 2018. https://iris.who.int/bitstream/handle/10665/330907/DI323-425-508-eng.pdf#page=58.

[1]

[2]

[3]

[4]

[5]

Revosimeline

Topic: Chemistry

References